 Connection
Samuel Mackintosh to Antineoplastic Agents
This is a "connection" page, showing publications Samuel Mackintosh has written about Antineoplastic Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.155 |
|
|
|
-
Xu C, Meng F, Park KS, Storey AJ, Gong W, Tsai YH, Gibson E, Byrum SD, Li D, Edmondson RD, Mackintosh SG, Vedadi M, Cai L, Tackett AJ, Kaniskan H?, Jin J, Wang GG. A NSD3-targeted PROTAC suppresses NSD3 and cMyc oncogenic nodes in cancer cells. Cell Chem Biol. 2022 03 17; 29(3):386-397.e9.
Score: 0.107
-
Li D, Yu X, Kottur J, Gong W, Zhang Z, Storey AJ, Tsai YH, Uryu H, Shen Y, Byrum SD, Edmondson RD, Mackintosh SG, Cai L, Liu Z, Aggarwal AK, Tackett AJ, Liu J, Jin J, Wang GG. Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic. Oncogene. 2022 06; 41(24):3328-3340.
Score: 0.028
-
Chu R, Alford SE, Hart K, Kothari A, Mackintosh SG, Kovak MR, Chambers TC. Mitotic arrest-induced phosphorylation of Mcl-1 revisited using two-dimensional gel electrophoresis and phosphoproteomics: nine phosphorylation sites identified. Oncotarget. 2016 Nov 29; 7(48):78958-78970.
Score: 0.019
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|